H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $400
Morgan Stanley Downgrades United Therapeutics(UTHR.US) to Hold Rating, Raises Target Price to $337
Oppenheimer Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $400
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $280 to $400
United Therapeutics (UTHR) Gets a Buy From Oppenheimer
United Therapeutics Analyst Ratings
Ladenburg Thalmann Downgrades United Therapeutics to Neutral From Buy, $319 Price Target
HC Wainwright Adjusts Price Target on United Therapeutics to $400 From $300, Maintains Buy Rating
H.C. Wainwright Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $400
United Therapeutics Analyst Ratings
Wells Fargo Sticks to Its Buy Rating for United Therapeutics (UTHR)
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
UBS Adjusts Price Target on United Therapeutics to $300 From $290, Maintains Buy Rating
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings